Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
NCT Number: NCT03367247
This research study is evaluating a new intervention, BOLSTER, which was designed to provide more support for patients with gynecologic and gastrointestinal cancers and their caregivers after a hospitalization.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02215, United States
Hospitalizations can be difficult for patients with cancer, especially when they are transitioning home. Patients and caregivers are often expected to perform complex medical and nursing tasks with little or no preparation. Patients and caregivers report high levels of unmet needs for information about how best to manage symptoms and new medical procedures (such as managing new tubes, lines or drains).
The study team has developed a research project which aims to address these needs. If a patient agrees to participate in the study, she will take part in a program called BOLSTER (Building Out Lifelines for Safety, Trust, Empowerment and Renewal). BOLSTER will provide patients and caregivers with education and skills training, symptom management, and support across care settings.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Patient inclusion criteria
Patient exclusion criteria
Caregiver inclusion criteria
Caregiver exclusion criteria:
BOLSTER provides patients and caregivers with education and skills training, symptom management, and support across care settings over a four-week period.
EDP provides patients and caregivers a single session of education and skills training, symptom management, and support.
Time frame: 1 month
≥50% consent-to-approach ratio
Time frame: 3 months
≥70% participants "agree" or "strongly agree" that they would recommend BOLSTER to other patients; and ≥70% participants "agreed or "strongly agreed" that they were satisfied with the BOLSTER intervention. Note that this measure only includes data from the RCT portion of the study, as the Phases 1a and 1b were designed to refine the intervention.
Dana-Farber Cancer Institute
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05132868
Adnexal Diseases, Digestive System Diseases
Palo Alto, California, United States
View Trial DetailsNCT03850912
Digestive System Diseases, Digestive System Neoplasms
Portland, Maine, United States
View Trial DetailsNCT06168825
Acceptance and Commitment Therapy, Blood Cancer
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05131815
Astrocytoma, Behavior
Los Angeles, California, United States
View Trial Details